login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
USA Market Overview
Canada Market Overview
Europe Market Overview
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Swing Trading Course
Account
Disclaimer
Affiliate
Contact
Privacy
APELLIS PHARMACEUTICALS INC (APLS) Stock News
USA
- NASDAQ:APLS -
US03753U1060
-
Common Stock
25.525
USD
+1 (+4.1%)
Last: 10/20/2025, 10:39:08 AM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
APLS Latest News, Press Relases and Analysis
All
Press Releases
4 hours ago - By: Apellis Pharmaceuticals, Inc.
New One-Year Data Reinforcing the Robust and Sustained Efficacy of EMPAVELI® (pegcetacoplan) in C3G and Primary IC-MPGN to be Presented at ASN Kidney Week
4 hours ago - By: Apellis Pharmaceuticals, Inc.
New One-Year Data Reinforcing the Robust and Sustained Efficacy of EMPAVELI® (pegcetacoplan) in C3G and Primary IC-MPGN to be Presented at ASN Kidney Week
4 days ago - By: Apellis Pharmaceuticals, Inc.
Apellis Pharmaceuticals to Host Conference Call on October 30, 2025, to Discuss Third Quarter 2025 Financial Results
4 days ago - By: Apellis Pharmaceuticals, Inc.
Apellis Pharmaceuticals to Host Conference Call on October 30, 2025, to Discuss Third Quarter 2025 Financial Results
5 days ago - By: Benzinga
Expert Outlook: Apellis Pharmaceuticals Through The Eyes Of 11 Analysts
24 days ago - By: Benzinga
12 Analysts Assess Apellis Pharmaceuticals: What You Need To Know
2 months ago - By: Apellis Pharmaceuticals, Inc.
Apellis Pharmaceuticals to Participate in Upcoming Investor Conferences
2 months ago - By: Stocktwits
Apellis Short Bets Edge Higher As Stock Jumps 45% Since Late July Q2 Report — Retail Traders Stay Wary
2 months ago - By: Apellis Pharmaceuticals, Inc.
Apellis Pharmaceuticals to Participate in Upcoming Investor Conferences
3 months ago - By: Yahoo Finance
- Mentions:
NVS
C
NOVN
Apellis Pharmaceuticals (APLS) Surges 17.6% on Higher Price Target
3 months ago - By: Stocktwits
- Mentions:
GS
MS
Retail Buzz Surges For Apellis As Goldman Hikes Price Target After Solid Syfovre Sales, FDA Win For Kidney Drug
3 months ago - By: Apellis Pharmaceuticals, Inc.
Apellis Pharmaceuticals Reports Second Quarter 2025 Financial Results
3 months ago - By: Apellis Pharmaceuticals, Inc.
Apellis Pharmaceuticals Reports Second Quarter 2025 Financial Results
3 months ago - By: Stocktwits
- Mentions:
MS
Why Retail Investors Are Turning Sharply Bullish On Apellis Pharmaceuticals
3 months ago - By: Apellis Pharmaceuticals, Inc.
FDA Approves Apellis’ EMPAVELI® (pegcetacoplan) as the First C3G and Primary IC-MPGN Treatment for Patients 12 and Older
3 months ago - By: Apellis Pharmaceuticals, Inc.
FDA Approves Apellis’ EMPAVELI® (pegcetacoplan) as the First C3G and Primary IC-MPGN Treatment for Patients 12 and Older
3 months ago - By: Apellis Pharmaceuticals, Inc.
Apellis Pharmaceuticals to Host Conference Call on July 31, 2025, to Discuss Second Quarter 2025 Financial Results
3 months ago - By: Apellis Pharmaceuticals, Inc.
Apellis Pharmaceuticals to Host Conference Call on July 31, 2025, to Discuss Second Quarter 2025 Financial Results
3 months ago - By: Zacks Investment Research
- Mentions:
SNY
ARVN
AKRO
Sanofi's Gene Therapy for Eye Disease Gets FDA's Fast Track Tag
3 months ago - By: Apellis Pharmaceuticals, Inc.
Apellis Announces Five Abstracts Accepted for Oral Presentation at the American Society of Retina Specialists (ASRS) Annual Scientific Meeting
3 months ago - By: Apellis Pharmaceuticals, Inc.
Apellis Announces Five Abstracts Accepted for Oral Presentation at the American Society of Retina Specialists (ASRS) Annual Scientific Meeting
4 months ago - By: Yahoo Finance
- Mentions:
MS
Morgan Stanley Raises PT on Apellis Pharmaceuticals (APLS) to $26, Keeps a Hold Rating
4 months ago - By: Yahoo Finance
Apellis Pharmaceuticals, Inc. (APLS) Insider Activity Signals Possible Market Mispricing
4 months ago - By: Yahoo Finance
- Mentions:
AQST
H.C. Wainwright Reaffirms Buy on Aquestive Therapeutics, Inc. (AQST) After FDA Approval
4 months ago - By: Apellis Pharmaceuticals, Inc.
Apellis to Receive up to $300 Million from Royalty Purchase Agreement with Sobi for Ex-U.S. Royalties of Aspaveli® (systemic pegcetacoplan)
4 months ago - By: Apellis Pharmaceuticals, Inc.
Apellis to Receive up to $300 Million from Royalty Purchase Agreement with Sobi for Ex-U.S. Royalties of Aspaveli® (systemic pegcetacoplan)
Please enable JavaScript to continue using this application.